|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM321103637 |
| 003 |
DE-627 |
| 005 |
20250228224922.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2021 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2021.108682
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n1070.xml
|
| 035 |
|
|
|a (DE-627)NLM321103637
|
| 035 |
|
|
|a (NLM)33549831
|
| 035 |
|
|
|a (PII)S1521-6616(21)00019-X
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Núñez, Isaac
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Common hematological values predict unfavorable outcomes in hospitalized COVID-19 patients
|
| 264 |
|
1 |
|c 2021
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 22.03.2021
|
| 500 |
|
|
|a Date Revised 21.12.2022
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2021 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a COVID-19 can range from asymptomatic to life-threatening. Early identification of patients who will develop severe disease is crucial. A number of scores and indexes have been developed to predict severity. However, most rely on measurements not readily available. We evaluated hematological and biochemical markers taken on admission and determined how predictive they were of development of critical illness or death. We observed that higher values of readily available tests, including neutrophil:lymphocyte ratio; derived neutrophil index; and troponin I were associated with a higher risk of death or critical care admission (P < 0.001). We show that common hematological tests can be helpful in determining early in the course of illness which patients are likely to develop severe forms, as well as allocating resources to those patients early, while avoiding overuse of limited resources in patients with reduced risk of progression to severe disease
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a COVID-19
|
| 650 |
|
4 |
|a Complete blood cell (CBC) count
|
| 650 |
|
4 |
|a Critical illness
|
| 650 |
|
4 |
|a Mortality predictors
|
| 650 |
|
4 |
|a SARS-CoV-2
|
| 650 |
|
7 |
|a Biomarkers
|2 NLM
|
| 700 |
1 |
|
|a Priego-Ranero, Ángel A
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a García-González, H Benjamín
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Jiménez-Franco, Brenda
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Bonilla-Hernández, Rebeca
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Domínguez-Cherit, Guillermo
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Merayo-Chalico, Javier
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Crispín, José C
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Barrera-Vargas, Ana
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Valdés-Ferrer, Sergio Iván
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 225(2021) vom: 01. Apr., Seite 108682
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnas
|
| 773 |
1 |
8 |
|g volume:225
|g year:2021
|g day:01
|g month:04
|g pages:108682
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2021.108682
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 225
|j 2021
|b 01
|c 04
|h 108682
|